Estrella Immunopharma Reports Decreased Net Losses and Progress in Clinical Trials

Estrella Immunopharma, Inc. reported a net loss of approximately $2.3 million for the three months ended June 30, 2026, a significant decrease from the $5.5 million loss recorded in the same period of the previous year. For the six months ended June 30, 2026, the company incurred a net loss of approximately $4.6 million, down from $7.6 million in the prior year. The reduction in losses is attributed to a decrease in research and development expenses, which fell to $1.4 million in the second quarter of 2026 from $4.7 million in 2025, primarily due to the timing of patient dosing milestones related to the STARLIGHT-1 clinical trial.

Total operating expenses for the second quarter of 2026 were approximately $2.1 million, down from $5.5 million in the same quarter of 2025. The company’s accumulated deficit as of June 30, 2026, stood at approximately $41.6 million. Estrella's cash and cash equivalents decreased to $146,670 from $1.4 million at the end of the previous fiscal year, reflecting ongoing operational expenditures and a working capital deficit of approximately $7.4 million.

Strategically, Estrella has made significant progress in its clinical development efforts. The company has dosed eleven patients in the STARLIGHT-1 clinical trial, which is focused on its lead product candidate, EB103, a T-cell therapy targeting CD19. The trial has progressed to include two Phase II patients as of June 30, 2026. The company has also entered into a Statement of Work with Eureka Therapeutics, Inc., which outlines a total fee of $33.5 million for achieving various milestones in the clinical trial.

In terms of financing, Estrella raised approximately $8.0 million through a registered direct offering and concurrent private placement in January 2026. Despite these efforts, management expressed concerns regarding the company's ability to continue as a going concern, citing recurring losses and the need for additional financing to meet operational requirements. The company has indicated that it may need to curtail or cease operations if it cannot secure adequate funding or generate significant revenue in the future.

Looking ahead, Estrella plans to continue advancing its clinical trials and regulatory efforts while managing its financial resources carefully. The company remains focused on its goal of developing innovative T-cell therapies for blood cancers and solid tumors, although it acknowledges the challenges posed by its current financial position and the competitive landscape in the biopharmaceutical industry.